Current trials for frontline therapy of mantle cell lymphoma

Raphael E Steiner, Jorge Romaguera, Michael Wang, Raphael E Steiner, Jorge Romaguera, Michael Wang

Abstract

Mantle cell lymphoma (MCL) is a rare and incurable subtype of non-Hodgkin's lymphoma that generally affects older individuals. However, the use of high-dose therapy and autologous stem cell transplant has improved significantly the prognosis of this hematological malignancy, but at the cost of increased toxicities, such as acute toxic death and secondary malignancies. But thanks to a rising understanding of the biology of MCL, the explosion of specifically targeted new efficacious agents, immunotherapy agents, and cellular therapies in the frontline setting, the prognosis of MCL is expected to improve dramatically.The initial treatment of MCL is currently not standardized and the therapeutic landscape of MCL is rapidly evolving. This review provides an extensive overview of the current frontline therapy trials for MCL and presents the results of innovative regimen, including some integrating novel agents and desintensified chemotherapy.

Keywords: Clinical trials; Frontline treatment; Mantle cell lymphoma; Novel agents.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL WM. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113(4):791–798. doi: 10.1002/cncr.23608.
    1. Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34(11):1256–1269. doi: 10.1200/JCO.2015.63.5904.
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. 2016;127(20):2375–90.
    1. Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910. doi: 10.1182/blood-2017-04-779736.
    1. Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue M-H, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, et al. Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL Network. Blood. 2017. 10.1182/blood-2017-07-797019.
    1. Narurkar R, Alkayem M, Liu D. SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma. Biomarker research. 2016;4:6. doi: 10.1186/s40364-016-0060-9.
    1. Martin P, Coleman M, Leonard JP. Progress in mantle-cell lymphoma. J Clin Oncol. 2009;27(4):481–483. doi: 10.1200/JCO.2008.19.5032.
    1. Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62–iv71. doi: 10.1093/annonc/mdx223.
    1. Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–8. 10.1111/bjh.14241.
    1. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016;172(1):80–88. doi: 10.1111/bjh.13796.
    1. Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, Stelitano C, Caracciolo F, Di Renzo N, Angrilli F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156(3):346–353. doi: 10.1111/j.1365-2141.2011.08958.x.
    1. Chen Y, Wang M, Romaguera J. Current regimens and novel agents for mantle cell lymphoma. Br J Haematol. 2014;167(1):3–18. doi: 10.1111/bjh.13000.
    1. Pophali P, Rosenthal AC, Tun H, Reeder CB, Micallef IN, Porrata L, Ansell SM, Johnston P, Inwards DJ. Autologous stem cell transplantation for mantle cell lymphoma in the elderly (≥65 years of age): the Mayo Clinic experience. Blood. 2017;130(Suppl 1):4536.
    1. Sawalha Y, Radivoyevitch T, Tullio K, Dean RM, Pohlman B, Hill BT, Kalaycio M, Majhail NS, Jagadeesh D. The role of upfront autologous hematopoietic cell transplantation in the treatment of mantle cell lymphoma, a population based study using the National Cancer Data Base (NCDB) Blood. 2017;130(Suppl 1):2009.
    1. Soubeyran P, Gressin R. Treatment of the elderly patient with mantle cell lymphoma. Hematology American Society of Hematology Education Program. 2016;2016(1):425–431.
    1. Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803–1813. doi: 10.1200/JCO.2016.71.3024.
    1. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621.
    1. Bao H, Bi C, Li W, Zhang X, Zhang H, Meng B, Fu K. Chimeric antigen receptor-engineered exosome as a drug delivery system in mantle cell lymphoma. Blood. 2017;130(Suppl 1):5561.
    1. Chen W, Du X, Luo C, Zhang Q, Wang M. Anti-CD19 chimeric antigen receptor T cells improve responses to chemotherapy-refractory mantle cell lymphoma: a case report. Blood. 2016;128(22):5393.
    1. Abramson JS, Palomba L, Gordon LI, Lunning M, Arnason J, Forero-Torres A, Albertson TM, Exton VS, Sutherland C, Xie B, et al. Transcend NHL 001: immunotherapy with the CD19-directed CAR T-cell product JCAR017 results in high complete response rates in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood. 2016;128(22):4192.
    1. Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, Melenhorst JJ, Wasik MA. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. Blood. 2017;130(23):2569–2572. doi: 10.1182/blood-2017-08-802413.
    1. Martin P, Ruan J, Leonard JP. The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. 2017;130(17):1881–1888. doi: 10.1182/blood-2017-05-737510.
    1. Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, Matasar MJ, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):2004–2009. doi: 10.1016/j.bbmt.2014.08.019.
    1. Abrahamsson A, Dahle N, Jerkeman M. Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma. 2011;52(10):1929–1935. doi: 10.3109/10428194.2011.587560.
    1. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013–7023. doi: 10.1200/JCO.2005.01.1825.
    1. Kahl BS, McGovern J, Blank J, Jaslowski A, Bayer G, Bottner WA, Rezazadeh H, McFarland T, Hei D, Smith J, et al. Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: a Wisconsin Oncology Network Study. Blood. 2004;104(11):1388.
    1. Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk. 2018;18(1):e61–e67. doi: 10.1016/j.clml.2017.10.006.
    1. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745. doi: 10.1182/blood-2015-03-635326.
    1. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516. doi: 10.1056/NEJMoa1306220.
    1. Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015;125(2):242–248. doi: 10.1182/blood-2014-08-597914.
    1. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–1026. doi: 10.1016/S1470-2045(14)70311-0.
    1. Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122(14):2412–2424. doi: 10.1182/blood-2013-02-482125.
    1. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56. doi: 10.1016/S1470-2045(15)00438-6.
    1. Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–2811. doi: 10.1200/JCO.2014.59.5363.
    1. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011;35(3):380–386. doi: 10.1016/j.leukres.2010.09.027.
    1. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13(7):716–723. doi: 10.1016/S1470-2045(12)70200-0.
    1. Goy A, Feldman TA, Leslie LA, Panchal RP, Nyirenda T, Skarbnik AP, Yannotti K, Zenreich J, Bejot CM, Stives S, et al. Phase Ib-II study of Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, w/ lenalidomide and rituximab in relapsed/refractory mantle cell lymphoma. Blood. 2017;130(Suppl 1):2785.
    1. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210. doi: 10.1016/S0140-6736(12)61763-2.
    1. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21. doi: 10.1186/s13045-016-0250-9.
    1. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2017. 10.1016/S0140-6736(17)33108-2.
    1. Albertsson-Lindblad A, Kolstad A, Laurell A, Raty R, Gronbaek K, Sundberg J, Pedersen LB, Ralfkiaer E, Karjalainen-Lindsberg ML, Sundstrom C, et al. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4. Blood. 2016.10.1182/blood-2016-03-704023.
    1. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–953. doi: 10.1056/NEJMoa1412096.
    1. Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Jr, Pozdnyakova O, et al. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016;172(2):208–218. doi: 10.1111/bjh.13818.
    1. Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125(1):48–55. doi: 10.1182/blood-2014-05-521898.
    1. Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017;176(5):759–769. doi: 10.1111/bjh.14480.
    1. Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W, et al. Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a phase II clinical trial. Blood. 2016;128(22):147.
    1. Wang ML, Lee, H., Thirumurthi, S., Chuang, H et al: ICML Lugano 2017 abstract. Ibrutinib-rituximab followed by reduced chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a window of opportunity to reduce chemo. Hematol Oncol, 35(S2): 142–143.
    1. Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118(19):5126–5129. doi: 10.1182/blood-2011-04-348656.
    1. Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, et al. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. Haematologica. 2015;100(12):e501–e504. doi: 10.3324/haematol.2015.132035.
    1. Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012;157(4):438–445. doi: 10.1111/j.1365-2141.2012.09086.x.
    1. Furtado M, Dyer MJ, Johnson R, Berrow M, Rule S. Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma—a phase II trial. Br J Haematol. 2014;165(4):575–578. doi: 10.1111/bjh.12769.
    1. Jermann M, Jost LM, Taverna C, Jacky E, Honegger HP, Betticher DC, Egli F, Kroner T, Stahel RA. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004;15(3):511–516. doi: 10.1093/annonc/mdh093.
    1. Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med. 2005;11(9):986–991. doi: 10.1038/nm1290.
    1. Grant C, Neelapu SS, Kwak LW, Dunleavy K, White T, Miller BW, Jaffe ES, Steinberg SM, Bird BH, Wilson WH. Eleven-year follow-up of idiotype vaccine and DA-EPOCH-rituximab in untreated mantle cell lymphoma: correlation of survival with idiotype immune response. Blood. 2011;118(21):2707.
    1. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–575. doi: 10.1016/S0140-6736(16)00739-X.
    1. Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, AS LC, Jacobson C, Davids MS, Brown JR, et al. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016;173(1):89–95. doi: 10.1111/bjh.13929.
    1. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99(9):3158–3162. doi: 10.1182/blood.V99.9.3158.
    1. Kruger PC, Cooney JP, Turner JH. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma. Cancer Biother Radiopharm. 2012;27(9):552–560. doi: 10.1089/cbr.2012.1275.
    1. Zelenetz AD, Noy A, Pandit-Taskar N, Scordo M, Rijo I, Zhou Y, O’Donoghue JA, Divgi C. Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol. 2006;24(18_suppl):7560.
    1. access date 23 February 2017 GtdmasotB.
    1. Puvvada SD, Guillen-Rodriguez J, Kumar A, Inclan L, Heard K, Rivera XI, Anwer F, Schatz JH, Mahadevan D, Persky DO. Phase 2 open-label study of bortezomib, cladribine, and rituximab in advanced, newly diagnosed, and relapsed/refractory mantle-cell and indolent lymphomas. Clin Lymphoma Myeloma Leuk. 2018;18(1):58–64. doi: 10.1016/j.clml.2017.09.001.
    1. Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, Leblanc M, Leonard JP, Friedberg JW, Baizer L, et al. Recommendations for clinical trial development in mantle cell lymphoma. J Natl Cancer Inst. 2017;109(1)
    1. Goy A. Mantle cell lymphoma: is it time for a new treatment paradigm? Hematol Oncol Clin North Am. 2016;30(6):1345–1370. doi: 10.1016/j.hoc.2016.07.014.
    1. Ahmed M, Zhang L, Nomie K, Lam L, Wang M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget. 2016;7(36):58638–48. 10.18632/oncotarget.10716.
    1. Ahmed M, Li L, Pinnix C, Dabaja B, Nomie K, Lam L, Wang M. ATM mutation and radiosensitivity: an opportunity in the therapy of mantle cell lymphoma. Crit Rev Oncol Hematol. 2016;107:14–19. doi: 10.1016/j.critrevonc.2016.08.008.
    1. Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, et al. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 2016;7(45):73558–73572. doi: 10.18632/oncotarget.12434.
    1. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, et al. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal. 2016;9(415):ra17. doi: 10.1126/scisignal.aac4380.
    1. ICML 2017 Abstract, Ferrero et al, KMT2D AND TP53 mutations predict poor pfs and os in mantle cell lymphoma receiving high-dose therapy and asct: the Fondazione Italiana Linfomi (FIL) MCL0208 phase III trial. Hematol Oncol, 35(S2): 94–95.
    1. Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015;126(13):1565–1574. doi: 10.1182/blood-2015-04-639542.
    1. Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, Yin CC, Young KH, Patel KP, Miranda RN, et al. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol. 2017. 10.1038/modpathol.2017.135.
    1. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol. 2015;8:63. doi: 10.1186/s13045-015-0161-1.
    1. Inamdar AA, Goy A, Ayoub NM, Attia C, Oton L, Taruvai V, Costales M, Lin YT, Pecora A, Suh KS. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget. 2016.
    1. Wheler J, Lee JJ, Kurzrock R. Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. Cancer Res. 2014;74(24):7181–7184. doi: 10.1158/0008-5472.CAN-14-2329.
    1. Kumar A. Novel agents in mantle cell lymphoma. Curr Oncol Rep. 2015;17(8):34. doi: 10.1007/s11912-015-0460-2.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe